Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shuang Xu, Yi Fu, Dan Xu, Shuang Han, Mingzhi Wu, Xinrong Ju, Meng Liu, De-Sheng Huang & Peng Guan. (2023) Mapping Research Trends of Medications for Multidrug-Resistant Pulmonary Tuberculosis Based on the Co-Occurrence of Specific Semantic Types in the MeSH Tree: A Bibliometric and Visualization-Based Analysis of PubMed Literature (1966–2020). Drug Design, Development and Therapy 17, pages 2035-2049.
Read now
Read now
Articles from other publishers (26)
Shahnaz Alom, Farak Ali, Dimpee Choudhury, Apurba Gohain, Abdul Baquee Ahmed & Md Kamaruz Zaman. 2023. Tubercular Drug Delivery Systems. Tubercular Drug Delivery Systems
289
305
.
A. V. Kukurika. (2021) Pretomanid: Clinical Trials and Prospects to Be Used in Treatment Regimens for Multiple and Extensive Drug Resistant Tuberculosis. Tuberculosis and Lung Diseases 99:6, pages 54-60.
Crossref
Crossref
Kun Li, Zhongping Yang, Jing Gu, Ming Luo, Jiaoyu Deng & Yaokai Chen. (2021) Characterization of pncA Mutations and Prediction of PZA Resistance in Mycobacterium tuberculosis Clinical Isolates From Chongqing, China. Frontiers in Microbiology 11.
Crossref
Crossref
Hui Xia, Susan van den Hof, Frank Cobelens, Yang Zhou, Bing Zhao, Shengfen Wang & Yanlin Zhao. (2020) Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China. BMC Infectious Diseases 20:1.
Crossref
Crossref
Elise A. Lamont, Nicholas A. Dillon & Anthony D. Baughn. (2020) The Bewildering Antitubercular Action of Pyrazinamide. Microbiology and Molecular Biology Reviews 84:2.
Crossref
Crossref
Michael A. Lyons. (2019) Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients. Antimicrobial Agents and Chemotherapy 63:12.
Crossref
Crossref
Anna Vassall. 2018. Prioritizing Development. Prioritizing Development
255
265
.
Charles Kozhikkadan Davis, K. Nasla, A. K. Anjana & G. K. Rajanikant. (2018) Taxifolin as dual inhibitor of Mtb DNA gyrase and isoleucyl-tRNA synthetase: in silico molecular docking, dynamics simulation and in vitro assays. In Silico Pharmacology 6:1.
Crossref
Crossref
Murat Cokol, Nurdan KuruEce BicakJonah Larkins-FordBree B. Aldridge. (2017)
Efficient measurement and factorization of high-order drug interactions in
Mycobacterium tuberculosis
. Science Advances 3:10.
Crossref
Crossref
Mohammad A.M. Momin, Sim J. Thien, Woravimol Krittaphol & Shyamal C. Das. (2017) Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of Pharmaceutical and Biomedical Analysis 135, pages 133-139.
Crossref
Crossref
Michio Kurosu & William DennyMegan Coffee. 2016. Advances in Tuberculosis Medicinal Chemistry. Advances in Tuberculosis Medicinal Chemistry
134
145
.
Michio Kurosu & William DennyWilliam A Denny. 2016. Advances in Tuberculosis Medicinal Chemistry. Advances in Tuberculosis Medicinal Chemistry
6
18
.
Xijun Wang, Aihua Zhang, Hui Sun, Ying Han & Guangli Yan. (2016) Discovery and development of innovative drug from traditional medicine by integrated chinmedomics strategies in the post-genomic era. TrAC Trends in Analytical Chemistry 76, pages 86-94.
Crossref
Crossref
Clive Page & Mario Cazzola. 2017. Pharmacology and Therapeutics of Asthma and COPD. Pharmacology and Therapeutics of Asthma and COPD
197
212
.
Andrew M. Thompson, Adrian Blaser, Brian D. Palmer, Scott G. Franzblau, Baojie Wan, Yuehong Wang, Zhenkun Ma & William A. Denny. (2015) Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy. Bioorganic & Medicinal Chemistry Letters 25:18, pages 3804-3809.
Crossref
Crossref
Zhi Chen, Jian-Qin Liang, Jin-He Wang, Shi-Sheng Feng & Guang-Yu Zhang. (2015) Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Tuberculosis 95:4, pages 490-496.
Crossref
Crossref
Sharon Nachman, Amina Ahmed, Farhana Amanullah, Mercedes C Becerra, Radu Botgros, Grania Brigden, Renee Browning, Elizabeth Gardiner, Richard Hafner, Anneke Hesseling, Cleotilde How, Patrick Jean-Philippe, Erica Lessem, Mamodikoe Makhene, Nontombi Mbelle, Ben Marais, Helen McIlleron, David F McNeeley, Carl Mendel, Stephen Murray, Eileen Navarro, E Gloria Anyalechi, Ariel R Porcalla, Clydette Powell, Mair Powell, Mona Rigaud, Vanessa Rouzier, Pearl Samson, H Simon Schaaf, Seema Shah, Jeff Starke, Soumya Swaminathan, Eric Wobudeya & Carol Worrell. (2015) Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. The Lancet Infectious Diseases 15:6, pages 711-720.
Crossref
Crossref
Brian D. Palmer, Hamish S. Sutherland, Adrian Blaser, Iveta Kmentova, Scott G. Franzblau, Baojie Wan, Yuehong Wang, Zhenkun Ma, William A. Denny & Andrew M. Thompson. (2015)
Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6
S
)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5
H
-imidazo[2,1-
b
][1,3]oxazine (PA-824)
. Journal of Medicinal Chemistry 58:7, pages 3036-3059.
Crossref
Crossref
A. M. Upton, S. Cho, T. J. Yang, Y. Kim, Y. Wang, Y. Lu, B. Wang, J. Xu, K. Mdluli, Z. Ma & S. G. Franzblau. (2015)
In Vitro
and
In Vivo
Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis
. Antimicrobial Agents and Chemotherapy 59:1, pages 136-144.
Crossref
Crossref
Bavesh Davandra Kana, Petros C. Karakousis, Tanya Parish & Thomas Dick. (2014) Future target-based drug discovery for tuberculosis?. Tuberculosis 94:6, pages 551-556.
Crossref
Crossref
Clive Page & Mario Cazzola. (2014) Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. European Respiratory Journal 44:2, pages 475-482.
Crossref
Crossref
Jim Werngren, Maria Wijkander, Nasrin Perskvist, V. Balasubramanian, Vasan K. Sambandamurthy, Camilla Rodrigues & Sven Hoffner. (2014)
In Vitro
Activity of AZD5847 against Geographically Diverse Clinical Isolates of Mycobacterium tuberculosis
. Antimicrobial Agents and Chemotherapy 58:7, pages 4222-4223.
Crossref
Crossref
H. Simon Schaaf, Anthony J. Garcia-Prats, Anneke C. Hesseling & James A. Seddon. (2014) Managing multidrug-resistant tuberculosis in children. Current Opinion in Infectious Diseases 27:3, pages 211-219.
Crossref
Crossref
Abdullah Alsultan & Charles A. Peloquin. (2014) Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update. Drugs 74:8, pages 839-854.
Crossref
Crossref
Yong-Soo Kwon, Byeong-Ho Jeong & Won-Jung Koh. (2014) Tuberculosis. Current Opinion in Pulmonary Medicine 20:3, pages 280-286.
Crossref
Crossref
Anthony J. Hickey, Amit Misra & P. Bernard Fourie. (2013) Dry Powder Antibiotic Aerosol Product Development: Inhaled Therapy for Tuberculosis. Journal of Pharmaceutical Sciences 102:11, pages 3900-3907.
Crossref
Crossref